Compounds > temozolomide
Page last updated: 2024-08-16

temozolomide and isomethyleugenol

temozolomide has been researched along with isomethyleugenol in 58 studies

Research

Studies (58)

TimeframeStudies, this research(%)All Research%
pre-19904 (6.90)18.7374
1990's2 (3.45)18.2507
2000's7 (12.07)29.6817
2010's30 (51.72)24.3611
2020's15 (25.86)2.80

Authors

AuthorsStudies
Catapano, CV; D'Incalci, M; Erba, E; Filippeschi, S; Zucchetti, M1
Tisdale, MJ2
Broggini, M; Catapano, CV; Citti, L; D'Incalci, M; Erba, E; Mariani, L; Ponti, M1
Gerson, SL; Liu, L; Markowitz, S1
Berger, MS; Blank, A; Bobola, MS; Silber, JR; Tseng, SH1
Berger, MS; Hirose, Y; Katayama, M; Mirzoeva, OK; Pieper, RO1
Altundag, K; Altundag, MB; Altundag, O; Boruban, C; Turen, S1
Aldape, K; Black, PM; Chakravarti, A; Erkkinen, MG; Gilbert, MR; Loeffler, JS; Mehta, M; Nestler, U; Stupp, R1
Del Maestro, R; Guiot, MC; Kavan, P; Lambert, C; Leblanc, R; Muanza, T; Panet-Raymond, V; Roberge, D; Shakibnia, L; Shenouda, G; Souhami, L1
Boeckmann, L; Emmert, S; Gutzmer, R; Has, C; Kunz, M; Kuschal, C; Laspe, P; Struever, D; Thoms, KM1
Ballman, KA; Carlson, BL; Decker, PA; Giannini, C; Grogan, PT; James, CD; Kitange, GJ; Mladek, AC; Sarkaria, JN; Schroeder, MA; Wu, W1
Cheng, AL; Kuo, KT; Kuo, LT; Lee, WC; Lin, CH; Lin, YT; Lu, YS; Tasi, JC; Tseng, HM; Tseng, SH; Tu, YK; Wu, PF; Wu, RM; Yang, CH1
Bilbao, JM; Del Maestro, RF; Fazl, M; Guiot, MC; Oh, J; Perry, JR; Tsao, MN1
Agarwal, N; Ahluwalia, MS; Barnett, GH; Brewer, CJ; Elson, P; Peereboom, DM; Shepard, DR; Stevens, GH; Suh, JH; Toms, SA; Vogelbaum, MA; Weil, RJ1
Blechschmidt, C; Czabanka, M; Koch, A; Misch, M; Plotkin, M; Stockhammer, F; Tuettenberg, J; Vajkoczy, P1
Camaioni, E; Dantzer, F; Dorio, AS; Gold, B; Graziani, G; Leonetti, C; Muzi, A; Pellicciari, R; Scarsella, M; Shah, GM; Tentori, L; Xu, W; Zhang, J1
Belinsky, SA; Bernauer, AM; Burki, EA; Costello, JF; Crowell, RE; Do, KC; Flores, KG; Gilliland, FD; Hong, C; Leng, S; Picchi, MA; Prados, MD; Stidley, CA; Tellez, CS; Tessema, M; Willink, RP; Yingling, CM1
Hirose, Y; Kanai, R; Louis, DN; Martuza, RL; Rabkin, SD; Sgubin, D; Wakimoto, H; Yip, S; Zaupa, CM1
Chatzisotiriou, A; Eleftheraki, AG; Fountzilas, G; Iliadis, G; Kotoula, V; Lambaki, S; Misailidou, D; Selviaridis, P; Televantou, D1
Ewelt, C; Felsberg, J; Jakobs, O; Martus, P; Meinel, T; Reifenberger, G; Stummer, W1
Carlson, BL; Cen, L; Decker, PA; Gupta, SK; Kitange, GJ; Lomberk, GA; Mladek, AC; Pokorny, JL; Sarkaria, JN; Schroeder, MA; Urrutia, RA; Wu, W1
Geng, J; Luo, H; Pu, Y; Wu, X; Xu, W; Yang, Z; Zhou, Z1
Abrams, JS; Conley, BA; Freidlin, B; Korn, EL; McShane, LM; Polley, MY1
Chamberlain, MC1
Balañà, C; Capdevila, L; Carrato, C; Cros, S; Cuadra, JL; Etxaniz, O; Hostalot, C; Massuet, A; Ramirez, JL; Romeo, M; Sanz, C; Villà, S1
Ohta, H; Sato, Y; Takeshima, H; Uehara, H; Yamasaki, K; Yamashita, S; Yokogami, K1
Chapet, S; Lévy, S; Mazeron, JJ1
He, W; Liu, R; Yang, SH; Yuan, F1
Cai, Q; Chen, Q; Daofeng, T; Dong, H; Guo, Z; Ji, B; Liu, B; Liu, Y; Wang, J; Wang, L; Wu, L; Zhang, S; Zhu, X1
Cloughesy, TF; Ha, W; Hitchins, MP; Lai, A; McDonald, KL; Nguyen, HN; Nowak, AK; Rapkins, RW; Wang, F1
Benecke, R; Grossmann, A; Hildebrandt, G; Kirschstein, T; Piek, J; Rösche, J1
Mohile, NA1
Gallo, JM; Pickard, AJ; Wang, T1
Choi, SH; Heo, DS; Jung, HW; Kim, DG; Kim, IH; Kim, SK; Kim, TM; Lee, SH; Lee, ST; Park, CK1
Back, M; Brazier, D; Cook, R; Gzell, C; Harris, G; Jayamanne, D; Kastelan, M; Khasraw, M; Louw, S; Parkinson, J; Schembri, G; Wheeler, H1
Cai, J; Dinislam, M; Duan, C; Gao, F; Gao, W; Han, B; Jiang, C; Kang, C; Lin, L; Meng, X; Wang, R; Wu, P1
Han, P; Lee, A; Malakhov, N; Schreiber, D; Sheth, N; Wang, A1
Bähr, O; Belka, C; Braun, C; Gerlach, R; Glas, M; Goldbrunner, R; Hänel, M; Hattingen, E; Hau, P; Herrlinger, U; Junold, N; Kebir, S; Kortmann, RD; Krex, D; Mack, F; Niessen, M; Proescholdt, M; Rohde, V; Sabel, M; Schäfer, N; Schaub, C; Schlegel, U; Schmidt-Graf, F; Steinbach, JP; Stuplich, M; Tzaridis, T; Vatter, H; Weyerbrock, A1
Sartore-Bianchi, A; Siena, S1
Bahador, M; Bifulco, E; Bindesbøll, C; Brekke, J; Chekenya, M; Engelsen, A; Enger, PØ; Gjertsen, BT; Goplen, D; Gras Navarro, A; Lie, SA; Rahman, MA; Sarowar, S; Selheim, F; Simonsen, A; Waha, A1
Berglund, AE; Etame, AB; MacAulay, RJ; Mulé, JJ; Wang, D; Wu, Q1
Ichimura, K; Igaki, H; Matsushita, Y; Miyakita, Y; Narita, Y; Ohno, M; Takahashi, M1
Carrato, A; Esteban, J; Gutiérrez, JA; Ley, L; Torres, J; Vaz Salgado, MA1
Caraglia, M; Ottaiano, A1
Pagani, F; Pietrantonio, F; Randon, G1
Chen, WJ; Han, H; He, XS; Kang, EM; Liu, WP; Lv, JN; Wang, GH; Wang, J; Yu, YB; Zhang, W; Zhang, X; Zhang, YL1
Cheng, H; Dai, X; Hu, Y; Wang, H; Wang, J; Wu, B; Ye, L1
Anderson, SK; Brinkmann, D; Brown, P; Hunt, C; Kabat, B; Kaufmann, T; Kemp, B; Kizilbash, S; Laack, NN; Lowe, V; Pafundi, D; Ruff, M; Sarkaria, J; Seaberg, M; Uhm, J; Vogen, D; Wan Chan Tseung, HS; Yan, E; Zakhary, M; Zhang, Y1
Kleszcz, R; Krajka-Kuźniak, V; Kruhlenia, N; Majchrzak-Celińska, A; Misiorek, JO; Przybyl, L; Rolle, K1
Bronsema, A; Guerreiro, H; Kresbach, C; Rutkowski, S; Schüller, U; Winkler, B1
Brandner, S; Cheng, HY; Dawson, S; Faulkner, CL; Higgins, JPT; Jefferies, S; Kelly, C; Kurian, KM; McAleenan, A; Schmidt, L; Spiga, F; Wragg, C1
Fujii, T; Ichimura, K; Kawauchi, D; Kobayashi, T; Kondo, A; Nakano, T; Narita, Y; Sasaki, N; Satomi, K; Takahashi, M; Tomiyama, A; Uchida, E; Wada, K; Yamamuro, S; Yoshino, A1
French, PJ; Golfinopoulos, V; Gorlia, T; Tesileanu, CMS; van den Bent, MJ1
Andrini, E; Brighi, N; Campana, D; Donati, G; Lamberti, G; Lisotti, A; Manuzzi, L; Mosconi, C1
Birkl-Toeglhofer, AM; Brawanski, KR; Freyschlag, CF; Haybaeck, J; Hoeftberger, R; Manzl, C; Sprung, S; Ströbel, T; Thomé, C1
Gao, Z; Hu, R; Li, M; Li, Y; Liu, C; Mei, M; Pang, B; Ren, Y; Wang, Y; Yang, J; Zhang, B; Zhang, X; Zhou, X1
Camenisch Gross, U; Hofer, S; Lehnick, D; Leske, H; Leske, S; Neidert, MC; Rushing, EJ; Weller, M1

Reviews

3 review(s) available for temozolomide and isomethyleugenol

ArticleYear
[Management of gliomas].
    Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique, 2014, Volume: 18, Issue:5-6

    Topics: Age Factors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Chemoradiotherapy; Chromosome Deletion; Chromosomes, Human, Pair 1; Clinical Trials as Topic; Combined Modality Therapy; Dacarbazine; Dose Fractionation, Radiation; Drug Resistance, Neoplasm; Glioma; Humans; Lomustine; Methylation; Multicenter Studies as Topic; Neoplasm Proteins; Neurosurgical Procedures; O(6)-Methylguanine-DNA Methyltransferase; Procarbazine; Radiotherapy Dosage; Radiotherapy, Intensity-Modulated; Temozolomide; Treatment Outcome; Vincristine

2014
How I treat glioblastoma in older patients.
    Journal of geriatric oncology, 2016, Volume: 7, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Geriatric Assessment; Glioblastoma; Humans; Isocitrate Dehydrogenase; Methylation; Middle Aged; Prognosis; Promoter Regions, Genetic; Quality of Life; Seizures; Standard of Care; Temozolomide; Tumor Suppressor Proteins

2016
MGMT promoter methylation testing to predict overall survival in people with glioblastoma treated with temozolomide: a comprehensive meta-analysis based on a Cochrane Systematic Review.
    Neuro-oncology, 2021, 09-01, Volume: 23, Issue:9

    Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Glioblastoma; Glioma; Humans; Methylation; Promoter Regions, Genetic; Temozolomide; Tumor Suppressor Proteins

2021

Trials

4 trial(s) available for temozolomide and isomethyleugenol

ArticleYear
Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme.
    Journal of neuro-oncology, 2010, Volume: 98, Issue:1

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Disease-Free Survival; DNA Modification Methylases; DNA Repair Enzymes; Erlotinib Hydrochloride; Female; Glioblastoma; Humans; Karnofsky Performance Status; Magnetic Resonance Imaging; Male; Methylation; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Radiotherapy; Temozolomide; Tumor Suppressor Proteins; Young Adult

2010
Neoadjuvant cisplatin plus temozolomide versus standard treatment in patients with unresectable glioblastoma or anaplastic astrocytoma: a differential effect of MGMT methylation.
    Journal of neuro-oncology, 2014, Volume: 117, Issue:1

    Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Chemotherapy, Adjuvant; Cisplatin; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Female; Glioblastoma; Humans; Male; Methylation; Middle Aged; Neoadjuvant Therapy; Radiation-Sensitizing Agents; Retrospective Studies; Survival Analysis; Temozolomide; Treatment Outcome; Tumor Suppressor Proteins; Young Adult

2014
Tumor growth patterns of MGMT-non-methylated glioblastoma in the randomized GLARIUS trial.
    Journal of cancer research and clinical oncology, 2018, Volume: 144, Issue:8

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cell Growth Processes; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Female; Glioblastoma; Humans; Irinotecan; Magnetic Resonance Imaging; Male; Methylation; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Radiotherapy; Temozolomide; Tumor Suppressor Proteins

2018
Initial Results of a Phase 2 Trial of
    International journal of radiation oncology, biology, physics, 2021, 08-01, Volume: 110, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Immunological; Bevacizumab; Brain Neoplasms; Chemotherapy, Adjuvant; Cognition; Confidence Intervals; Dihydroxyphenylalanine; Dose Fractionation, Radiation; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Methylation; Middle Aged; O(6)-Methylguanine-DNA Methyltransferase; Positron-Emission Tomography; Progression-Free Survival; Prospective Studies; Quality of Life; Radiopharmaceuticals; Radiotherapy, Image-Guided; Temozolomide; Young Adult

2021

Other Studies

51 other study(ies) available for temozolomide and isomethyleugenol

ArticleYear
Temozolomide induced differentiation of K562 leukemia cells is not mediated by gene hypomethylation.
    Biochemical pharmacology, 1989, Jul-01, Volume: 38, Issue:13

    Topics: Blotting, Northern; Cell Cycle; Cell Differentiation; Dacarbazine; DNA Damage; DNA, Neoplasm; Flow Cytometry; Genes, ras; Humans; Kinetics; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Methylation; Proto-Oncogenes; Temozolomide; Tumor Cells, Cultured

1989
Antitumour imidazotetrazines--XVIII. Modification of the level of 5-methylcytosine in DNA by 3-substituted imidazotetrazinones.
    Biochemical pharmacology, 1989, Apr-01, Volume: 38, Issue:7

    Topics: 5-Methylcytosine; Antineoplastic Agents; Cell Division; Cell Line; Cytosine; Dacarbazine; DNA; DNA (Cytosine-5-)-Methyltransferases; Dose-Response Relationship, Drug; Humans; Imidazoles; Lymphocytes; Methylation; Temozolomide

1989
Antitumour imidazotetrazines-X. Effect of 8-carbamoyl-3-methylimidazo[5,1-d]-1,2,3,5-tetrazin-4-(3H)-one (CCRG 81045; M & B 39831; NSC 362856) on DNA methylation during induction of haemoglobin synthesis in human leukaemia cell line K562.
    Biochemical pharmacology, 1986, Jan-15, Volume: 35, Issue:2

    Topics: 5-Methylcytosine; Antineoplastic Agents; Cell Differentiation; Cell Line; Cytosine; Dacarbazine; DNA Replication; DNA, Neoplasm; Gene Expression Regulation; Globins; Hemoglobins; Humans; Imidazoles; Leukemia, Erythroblastic, Acute; Methylation; Temozolomide; Templates, Genetic; Time Factors

1986
In vitro and in vivo methazolastone-induced DNA damage and repair in L-1210 leukemia sensitive and resistant to chloroethylnitrosoureas.
    Cancer research, 1987, Sep-15, Volume: 47, Issue:18

    Topics: Animals; Antineoplastic Agents; Carmustine; Dacarbazine; DNA Damage; DNA Repair; DNA, Neoplasm; Drug Resistance; Flow Cytometry; Leukemia L1210; Methylation; Methyltransferases; Mice; O(6)-Methylguanine-DNA Methyltransferase; Temozolomide

1987
Mismatch repair mutations override alkyltransferase in conferring resistance to temozolomide but not to 1,3-bis(2-chloroethyl)nitrosourea.
    Cancer research, 1996, Dec-01, Volume: 56, Issue:23

    Topics: Antineoplastic Agents, Alkylating; Carmustine; Colonic Neoplasms; Dacarbazine; DNA Adducts; DNA Damage; DNA Repair; Drug Resistance, Neoplasm; Enzyme Inhibitors; Guanine; Humans; Methylation; Methyltransferases; Microsatellite Repeats; Mutation; O(6)-Methylguanine-DNA Methyltransferase; Phenotype; Temozolomide; Tumor Cells, Cultured; Tumor Stem Cell Assay

1996
Role of O6-methylguanine-DNA methyltransferase in resistance of human brain tumor cell lines to the clinically relevant methylating agents temozolomide and streptozotocin.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 1996, Volume: 2, Issue:4

    Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Drug Resistance, Neoplasm; Guanine; Humans; Methyl Methanesulfonate; Methylation; Methylnitronitrosoguanidine; O(6)-Methylguanine-DNA Methyltransferase; Streptozocin; Temozolomide; Tumor Cells, Cultured

1996
Akt activation suppresses Chk2-mediated, methylating agent-induced G2 arrest and protects from temozolomide-induced mitotic catastrophe and cellular senescence.
    Cancer research, 2005, Jun-01, Volume: 65, Issue:11

    Topics: Antineoplastic Agents, Alkylating; Astrocytes; Cell Line, Transformed; Cell Line, Tumor; Checkpoint Kinase 2; Dacarbazine; Enzyme Activation; G2 Phase; Glioblastoma; Humans; Methylation; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Temozolomide

2005
Phenytoin may increase the efficacy of temozolomide by methylating DNA-repair enzyme, O6-methylguanine-DNA methyltransferase in patients with glioblastoma.
    Medical hypotheses, 2005, Volume: 65, Issue:4

    Topics: Dacarbazine; DNA Repair; Glioblastoma; Humans; Methylation; O(6)-Methylguanine-DNA Methyltransferase; Phenytoin; Temozolomide

2005
Temozolomide-mediated radiation enhancement in glioblastoma: a report on underlying mechanisms.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2006, Aug-01, Volume: 12, Issue:15

    Topics: Animals; Apoptosis; Cell Line, Tumor; Combined Modality Therapy; Dacarbazine; Disease Models, Animal; DNA Damage; Glioblastoma; Guanine; Humans; Methylation; Mice; Mice, Nude; O(6)-Methylguanine-DNA Methyltransferase; Structure-Activity Relationship; Temozolomide; Transplantation, Heterologous; Xenograft Model Antitumor Assays

2006
Accelerated hypofractionated intensity-modulated radiotherapy with concurrent and adjuvant temozolomide for patients with glioblastoma multiforme: a safety and efficacy analysis.
    International journal of radiation oncology, biology, physics, 2009, Feb-01, Volume: 73, Issue:2

    Topics: Adult; Aged; Analysis of Variance; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Disease-Free Survival; Dose Fractionation, Radiation; Drug Administration Schedule; Female; Glioblastoma; Humans; Male; Methylation; Middle Aged; O(6)-Methylguanine-DNA Methyltransferase; Radiotherapy, Intensity-Modulated; Retrospective Studies; Temozolomide; Treatment Outcome; Tumor Burden

2009
Modulation of the efficacy of temozolomide and dacarbazine melanoma treatment by DNA-repair factors in vivo and in vitro.
    International journal of clinical pharmacology and therapeutics, 2009, Volume: 47, Issue:1

    Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Cell Survival; Clinical Trials as Topic; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Lymphocytes; Melanoma; Methylation; MutL Protein Homolog 1; MutS Homolog 2 Protein; Nuclear Proteins; Prodrugs; Promoter Regions, Genetic; RNA, Messenger; Temozolomide; Tumor Suppressor Proteins

2009
Radiosensitizing effects of temozolomide observed in vivo only in a subset of O6-methylguanine-DNA methyltransferase methylated glioblastoma multiforme xenografts.
    International journal of radiation oncology, biology, physics, 2009, Sep-01, Volume: 75, Issue:1

    Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Combined Modality Therapy; Dacarbazine; Drug Administration Schedule; Genes, erbB-1; Genes, p53; Glioblastoma; Humans; Methylation; Mice; O(6)-Methylguanine-DNA Methyltransferase; PTEN Phosphohydrolase; Radiation-Sensitizing Agents; Random Allocation; Survival Analysis; Temozolomide; Xenograft Model Antitumor Assays

2009
O(6)-Methylguanine-DNA methyltransferase expression and prognostic value in brain metastases of lung cancers.
    Lung cancer (Amsterdam, Netherlands), 2010, Volume: 68, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Female; Humans; Immunohistochemistry; Lung Neoplasms; Male; Methylation; Middle Aged; Predictive Value of Tests; Prognosis; Promoter Regions, Genetic; Reverse Transcriptase Polymerase Chain Reaction; Survival Analysis; Temozolomide; Tumor Suppressor Proteins

2010
Recurrent PNET with MGMT methylation responds to temozolomide.
    The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques, 2009, Volume: 36, Issue:5

    Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Humans; Magnetic Resonance Imaging; Male; Methylation; Neuroectodermal Tumors, Primitive; O(6)-Methylguanine-DNA Methyltransferase; Temozolomide

2009
Continuous low-dose temozolomide and celecoxib in recurrent glioblastoma.
    Journal of neuro-oncology, 2010, Volume: 100, Issue:3

    Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Celecoxib; Cyclooxygenase 2 Inhibitors; Dacarbazine; Disease-Free Survival; DNA Modification Methylases; DNA Repair Enzymes; Female; Fluorine Radioisotopes; Follow-Up Studies; Glioblastoma; Humans; Male; Methylation; Middle Aged; Positron-Emission Tomography; Pyrazoles; Retrospective Studies; Sulfonamides; Temozolomide; Tumor Suppressor Proteins; Tyrosine

2010
Pharmacological inhibition of poly(ADP-ribose) polymerase (PARP) activity in PARP-1 silenced tumour cells increases chemosensitivity to temozolomide and to a N3-adenine selective methylating agent.
    Current cancer drug targets, 2010, Volume: 10, Issue:4

    Topics: Animals; Antineoplastic Agents; Blotting, Western; Cell Division; Cell Line, Tumor; Dacarbazine; Drug Synergism; Enzyme Inhibitors; Flow Cytometry; G2 Phase; HeLa Cells; Humans; Melanoma, Experimental; Methylation; Mice; Netropsin; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Temozolomide

2010
The A/G allele of rs16906252 predicts for MGMT methylation and is selectively silenced in premalignant lesions from smokers and in lung adenocarcinomas.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2011, Apr-01, Volume: 17, Issue:7

    Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Antineoplastic Agents, Alkylating; beta-Galactosidase; Cell Line, Tumor; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Epigenesis, Genetic; Female; Gene Expression Regulation, Neoplastic; Genes, Reporter; Genetic Association Studies; Haplotypes; Humans; Linkage Disequilibrium; Luciferases; Lung Neoplasms; Male; Methylation; Middle Aged; Polymorphism, Single Nucleotide; Precancerous Conditions; Promoter Regions, Genetic; Smoking; Sputum; Temozolomide; Transcription, Genetic; Tumor Suppressor Proteins

2011
Oncolytic virus-mediated manipulation of DNA damage responses: synergy with chemotherapy in killing glioblastoma stem cells.
    Journal of the National Cancer Institute, 2012, Jan-04, Volume: 104, Issue:1

    Topics: Animals; Antineoplastic Agents, Alkylating; Ataxia Telangiectasia Mutated Proteins; Brain Neoplasms; Cell Cycle Proteins; Cell Line, Tumor; Cell Survival; Chlorocebus aethiops; Dacarbazine; DNA Damage; DNA Modification Methylases; DNA Repair; DNA Repair Enzymes; DNA-Binding Proteins; Female; Gene Knockdown Techniques; Genetic Vectors; Glioblastoma; Humans; Immunoblotting; Immunohistochemistry; Methylation; Mice; Mice, Nude; Neoplastic Stem Cells; Oncolytic Virotherapy; Polymerase Chain Reaction; Protein Serine-Threonine Kinases; Simplexvirus; Temozolomide; Tumor Suppressor Proteins; Vero Cells; Virus Replication

2012
Volumetric and MGMT parameters in glioblastoma patients: survival analysis.
    BMC cancer, 2012, Jan-03, Volume: 12

    Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Disease-Free Survival; DNA Modification Methylases; DNA Repair Enzymes; Female; Gene Expression Profiling; Glioblastoma; Humans; Magnetic Resonance Imaging; Male; Methylation; Middle Aged; Multivariate Analysis; Predictive Value of Tests; Prognosis; Prospective Studies; Survival Analysis; Temozolomide; Tumor Burden; Tumor Suppressor Proteins

2012
Prospective cohort study of radiotherapy with concomitant and adjuvant temozolomide chemotherapy for glioblastoma patients with no or minimal residual enhancing tumor load after surgery.
    Journal of neuro-oncology, 2012, Volume: 108, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cohort Studies; Combined Modality Therapy; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Magnetic Resonance Imaging; Male; Methylation; Middle Aged; Postoperative Complications; Radiotherapy; Retrospective Studies; Temozolomide; Treatment Outcome; Tumor Suppressor Proteins; Young Adult

2012
Inhibition of histone deacetylation potentiates the evolution of acquired temozolomide resistance linked to MGMT upregulation in glioblastoma xenografts.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2012, Aug-01, Volume: 18, Issue:15

    Topics: Acetylation; Animals; Antineoplastic Agents, Alkylating; Blotting, Western; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Glioblastoma; Histone Deacetylase Inhibitors; Histones; Humans; Hydroxamic Acids; Kaplan-Meier Estimate; Methylation; Mice; Promoter Regions, Genetic; Reverse Transcriptase Polymerase Chain Reaction; Temozolomide; Tumor Suppressor Proteins; Up-Regulation; Vorinostat; Xenograft Model Antitumor Assays

2012
Methylation mediated silencing of miR-23b expression and its role in glioma stem cells.
    Neuroscience letters, 2012, Oct-24, Volume: 528, Issue:2

    Topics: Antineoplastic Agents; Azacitidine; Brain Neoplasms; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Decitabine; Down-Regulation; Epigenesis, Genetic; Gene Silencing; Glioma; Humans; Methylation; MicroRNAs; Neoplastic Stem Cells; Promoter Regions, Genetic; Temozolomide

2012
Statistical and practical considerations for clinical evaluation of predictive biomarkers.
    Journal of the National Cancer Institute, 2013, Nov-20, Volume: 105, Issue:22

    Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; ErbB Receptors; Gefitinib; Glioblastoma; Humans; Indazoles; Interleukin-6; Kidney Neoplasms; Lung Neoplasms; Methylation; Molecular Targeted Therapy; Mutation; Neoplasms; Precision Medicine; Predictive Value of Tests; Pyrimidines; Quinazolines; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Sample Size; Sulfonamides; Temozolomide; Tumor Suppressor Proteins

2013
Treatment of newly diagnosed malignant glioma in the elderly people: new trials that impact therapy.
    International journal of clinical practice, 2013, Volume: 67, Issue:12

    Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Chemoradiotherapy; Dacarbazine; Glioblastoma; Guanosine; Humans; Methylation; Middle Aged; Radiotherapy Dosage; Randomized Controlled Trials as Topic; Survival Rate; Temozolomide

2013
Case of primary diffuse leptomeningeal gliomatosis.
    Brain tumor pathology, 2014, Volume: 31, Issue:3

    Topics: Antineoplastic Agents, Alkylating; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Fatal Outcome; Humans; Magnetic Resonance Imaging; Male; Meningeal Neoplasms; Methylation; Middle Aged; Neoplasms, Neuroepithelial; Promoter Regions, Genetic; Radiotherapy; Temozolomide; Tumor Suppressor Proteins

2014
Chemotherapeutic effect of tamoxifen on temozolomide-resistant gliomas.
    Anti-cancer drugs, 2015, Volume: 26, Issue:3

    Topics: Animals; Antineoplastic Agents, Hormonal; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Electron Transport Complex I; Glioma; Humans; Male; Methylation; Mitochondria; Promoter Regions, Genetic; Rats, Sprague-Dawley; Tamoxifen; Temozolomide; Tumor Suppressor Proteins

2015
LRIG1, human EGFR inhibitor, reverses multidrug resistance through modulation of ABCB1 and ABCG2.
    Brain research, 2015, Jun-22, Volume: 1611

    Topics: ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Cell Line, Tumor; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Multiple; Drug Resistance, Neoplasm; ErbB Receptors; Glioblastoma; Humans; Membrane Glycoproteins; Methylation; Neoplasm Proteins; Promoter Regions, Genetic; RNA, Messenger; Temozolomide; Tumor Suppressor Proteins; Up-Regulation

2015
The MGMT promoter SNP rs16906252 is a risk factor for MGMT methylation in glioblastoma and is predictive of response to temozolomide.
    Neuro-oncology, 2015, Volume: 17, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Alleles; Antineoplastic Agents, Alkylating; Biomarkers; Brain Neoplasms; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Female; Genotype; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Methylation; Middle Aged; Polymorphism, Single Nucleotide; Promoter Regions, Genetic; Risk Factors; Temozolomide; Treatment Outcome; Tumor Suppressor Proteins

2015
[Perampanel in the treatment of a patient with glioblastoma multiforme without IDH1 mutation and without MGMT promotor methylation].
    Fortschritte der Neurologie-Psychiatrie, 2015, Volume: 83, Issue:5

    Topics: Alkylating Agents; Brain Neoplasms; Dacarbazine; Epilepsies, Partial; Excitatory Amino Acid Antagonists; Glioblastoma; Humans; Isocitrate Dehydrogenase; Magnetic Resonance Imaging; Male; Methylation; Middle Aged; Mutation; Nitriles; O(6)-Methylguanine-DNA Methyltransferase; Promoter Regions, Genetic; Pyridones; Survival Analysis; Temozolomide

2015
Histone Methylation by Temozolomide; A Classic DNA Methylating Anticancer Drug.
    Anticancer research, 2016, Volume: 36, Issue:7

    Topics: Animals; Antineoplastic Agents, Alkylating; Arginine; Dacarbazine; DNA Methylation; Histones; Humans; Lysine; Mass Spectrometry; Methylation; Temozolomide; Xenopus

2016
The survival significance of a measurable enhancing lesion after completing standard treatment for newly diagnosed glioblastoma.
    Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia, 2016, Volume: 34

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease-Free Survival; DNA Modification Methylases; DNA Repair Enzymes; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Methylation; Middle Aged; Retrospective Studies; Temozolomide; Treatment Outcome; Tumor Suppressor Proteins; Young Adult

2016
Survival Outcomes of Elderly Patients With Glioblastoma Multiforme in Their 75th Year or Older Treated With Adjuvant Therapy.
    International journal of radiation oncology, biology, physics, 2017, 07-15, Volume: 98, Issue:4

    Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Disease-Free Survival; DNA Modification Methylases; DNA Repair Enzymes; Glioblastoma; Humans; Kaplan-Meier Estimate; Methylation; Multivariate Analysis; Radiotherapy Dosage; Radiotherapy, Intensity-Modulated; Regression Analysis; Retrospective Studies; Temozolomide; Time Factors; Tumor Suppressor Proteins

2017
Loss of ATRX suppresses ATM dependent DNA damage repair by modulating H3K9me3 to enhance temozolomide sensitivity in glioma.
    Cancer letters, 2018, 04-10, Volume: 419

    Topics: Animals; Antineoplastic Agents, Alkylating; Ataxia Telangiectasia Mutated Proteins; Brain Neoplasms; Cell Line, Tumor; Cell Survival; DNA Damage; DNA Repair; Female; Gene Expression Regulation, Neoplastic; Gene Knockout Techniques; Glioma; Histones; Humans; Lysine; Methylation; Mice, Nude; Temozolomide; X-linked Nuclear Protein; Xenograft Model Antitumor Assays

2018
Patterns of care and outcomes of chemoradiation versus radiation alone for MGMT promoter unmethylated glioblastoma.
    Clinical neurology and neurosurgery, 2018, Volume: 170

    Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Cohort Studies; Databases, Factual; DNA Modification Methylases; DNA Repair Enzymes; Female; Follow-Up Studies; Glioblastoma; Humans; Male; Methylation; Middle Aged; Promoter Regions, Genetic; Survival Rate; Temozolomide; Treatment Outcome; Tumor Suppressor Proteins

2018
The right chance for temozolomide in metastatic colorectal cancer?
    Annals of oncology : official journal of the European Society for Medical Oncology, 2018, 08-01, Volume: 29, Issue:8

    Topics: Colorectal Neoplasms; DNA Modification Methylases; DNA Repair Enzymes; Humans; Irinotecan; Methylation; Salvage Therapy; Temozolomide; Tumor Suppressor Proteins

2018
Bortezomib administered prior to temozolomide depletes MGMT, chemosensitizes glioblastoma with unmethylated MGMT promoter and prolongs animal survival.
    British journal of cancer, 2019, Volume: 121, Issue:7

    Topics: Animals; Antineoplastic Agents; Bortezomib; Brain Neoplasms; Cell Line, Tumor; Drug Administration Schedule; Drug Resistance, Neoplasm; Glioblastoma; High-Throughput Nucleotide Sequencing; Humans; Kaplan-Meier Estimate; Methylation; Mice; Mice, Inbred NOD; Mice, SCID; Neoplasm Transplantation; O(6)-Methylguanine-DNA Methyltransferase; Polymerase Chain Reaction; Promoter Regions, Genetic; RNA, Messenger; Temozolomide; Transcription Factor RelA

2019
Paradoxical epigenetic regulation of XAF1 mediates plasticity towards adaptive resistance evolution in MGMT-methylated glioblastoma.
    Scientific reports, 2019, Oct-01, Volume: 9, Issue:1

    Topics: Adaptation, Physiological; Adaptor Proteins, Signal Transducing; Antineoplastic Agents, Alkylating; Apoptosis Regulatory Proteins; Cell Line, Tumor; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Epigenesis, Genetic; Evolution, Molecular; Glioblastoma; Humans; Methylation; Temozolomide; Tumor Suppressor Proteins

2019
Survival benefits of hypofractionated radiotherapy combined with temozolomide or temozolomide plus bevacizumab in elderly patients with glioblastoma aged ≥ 75 years.
    Radiation oncology (London, England), 2019, Nov-12, Volume: 14, Issue:1

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain; Brain Neoplasms; Combined Modality Therapy; Disease-Free Survival; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Magnetic Resonance Imaging; Male; Methylation; Radiation Dose Hypofractionation; Retrospective Studies; Temozolomide; Treatment Outcome

2019
Survey of treatment recommendations for elderly patients with glioblastoma.
    Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2020, Volume: 22, Issue:8

    Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Chemoradiotherapy; DNA Modification Methylases; DNA Repair Enzymes; Glioblastoma; Health Care Surveys; Humans; Methylation; Oncologists; Physical Functional Performance; Radiotherapy Dosage; Spain; Temozolomide; Tumor Suppressor Proteins

2020
MGMT Promoter Methylation as a Target In Metastatic Colorectal Cancer: Rapid Turnover and Use of Folates Alter its Study-Letter.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2020, 07-01, Volume: 26, Issue:13

    Topics: Capecitabine; Colorectal Neoplasms; DNA Modification Methylases; DNA Repair Enzymes; Humans; Methylation; Promoter Regions, Genetic; Temozolomide; Tumor Suppressor Proteins

2020
MGMT Promoter Methylation as a Target In Metastatic Colorectal Cancer: Rapid Turnover and Use of Folates Alter its Study-Response.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2020, 07-01, Volume: 26, Issue:13

    Topics: Capecitabine; Colorectal Neoplasms; DNA Modification Methylases; DNA Repair Enzymes; Humans; Methylation; Promoter Regions, Genetic; Temozolomide; Tumor Suppressor Proteins

2020
The different role of YKL-40 in glioblastoma is a function of MGMT promoter methylation status.
    Cell death & disease, 2020, 08-21, Volume: 11, Issue:8

    Topics: Adult; Brain Neoplasms; Chitinase-3-Like Protein 1; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Epigenesis, Genetic; Female; Glioblastoma; Humans; Male; Methylation; Middle Aged; Neoplasm Recurrence, Local; Promoter Regions, Genetic; Temozolomide; Tumor Suppressor Proteins

2020
Methylation associated miR-1246 contributes to poor prognosis in gliomas treated with temozolomide.
    Clinical neurology and neurosurgery, 2021, Volume: 200

    Topics: Brain Neoplasms; Cell Proliferation; Gene Expression Regulation, Neoplastic; Glioblastoma; Glioma; Humans; Methylation; MicroRNAs; Prognosis; Temozolomide

2021
COXIBs and 2,5-dimethylcelecoxib counteract the hyperactivated Wnt/β-catenin pathway and COX-2/PGE2/EP4 signaling in glioblastoma cells.
    BMC cancer, 2021, May-03, Volume: 21, Issue:1

    Topics: Aged; Antineoplastic Agents, Alkylating; Apoptosis; beta Catenin; Brain Neoplasms; Celecoxib; Cell Cycle; Cell Line, Tumor; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dinoprostone; DNA Modification Methylases; DNA Repair Enzymes; Dose-Response Relationship, Drug; Etoricoxib; Female; Glioblastoma; Humans; Isoxazoles; Lactones; Male; Methylation; Middle Aged; Neoplasm Proteins; Pyrazoles; Receptors, Prostaglandin E, EP4 Subtype; Sulfonamides; Sulfones; Temozolomide; Tumor Suppressor Proteins; Wnt Signaling Pathway

2021
Long-term survival of an adolescent glioblastoma patient under treatment with vinblastine and valproic acid illustrates importance of methylation profiling.
    Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery, 2022, Volume: 38, Issue:2

    Topics: Adolescent; Brain Neoplasms; Glioblastoma; Humans; Methylation; Prognosis; Temozolomide; Valproic Acid; Vinblastine

2022
Lomustine and nimustine exert efficient antitumor effects against glioblastoma models with acquired temozolomide resistance.
    Cancer science, 2021, Volume: 112, Issue:11

    Topics: Animals; Antineoplastic Agents; Brain Neoplasms; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Female; Glioblastoma; Histones; Humans; Injections, Intraperitoneal; Lomustine; Methylation; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Recurrence, Local; Nimustine; Salvage Therapy; Temozolomide; Tumor Suppressor Proteins; Xenograft Model Antitumor Assays

2021
MGMT promoter methylation determined by the MGMT-STP27 algorithm is not predictive for outcome to temozolomide in IDH-mutant anaplastic astrocytomas.
    Neuro-oncology, 2022, 04-01, Volume: 24, Issue:4

    Topics: Algorithms; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Glioblastoma; Humans; Methylation; Temozolomide; Tumor Suppressor Proteins

2022
Prospective Evaluation of
    Current oncology (Toronto, Ont.), 2023, 01-18, Volume: 30, Issue:2

    Topics: Antineoplastic Agents, Alkylating; DNA Modification Methylases; DNA Repair Enzymes; Humans; Methylation; Neuroendocrine Tumors; Prospective Studies; Temozolomide; Tumor Suppressor Proteins

2023
Influence of MMR, MGMT Promotor Methylation and Protein Expression on Overall and Progression-Free Survival in Primary Glioblastoma Patients Treated with Temozolomide.
    International journal of molecular sciences, 2023, Mar-24, Volume: 24, Issue:7

    Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Methylation; DNA Mismatch Repair; DNA Modification Methylases; DNA Repair Enzymes; Glioblastoma; Humans; Methylation; O(6)-Methylguanine-DNA Methyltransferase; Progression-Free Survival; Temozolomide; Tumor Suppressor Proteins

2023
Lysine methylation promotes NFAT5 activation and determines temozolomide efficacy in glioblastoma.
    Nature communications, 2023, 07-10, Volume: 14, Issue:1

    Topics: ErbB Receptors; Glioblastoma; Humans; Lysine; Methylation; NFATC Transcription Factors; Temozolomide; TNF Receptor-Associated Factor 6; Transcription Factors

2023
MGMT methylation pattern of long-term and short-term survivors of glioblastoma reveals CpGs of the enhancer region to be of high prognostic value.
    Acta neuropathologica communications, 2023, 08-28, Volume: 11, Issue:1

    Topics: DNA Modification Methylases; DNA Repair Enzymes; Glioblastoma; Humans; Isocitrate Dehydrogenase; Methylation; Prognosis; Prospective Studies; Retrospective Studies; Temozolomide; Tumor Suppressor Proteins

2023